ArticleBMC pregnancy and childbirth2026
Clinical outcomes of the short agonist stop protocol versus the long GnRH agonist protocol in poor ovarian responders undergoing IVF/ICSI: a retrospective analysis.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo assess the efficacy of the stop GnRH agonist/GnRH antagonist (STOP) protocol in improving in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) outcomes in patients with poor ovarian response (POR).
methodsPatients with POR who underwent IVF or ICSI at the Reproductive Center of Shanxi Women and Children Hospital between January 2023 and April 2024 were retrospectively enrolled according to the Bologna criteria for POR established by the European Society of Human Reproduction and Embryology in 2011. All received controlled ovarian stimulation (OS) and were assigned to a control group, which underwent the conventional short-acting long protocol, or the STOP group. Ovulation induction parameters and clinical outcomes were compared to assess the effectiveness of the STOP protocol.
resultsA total of 103 patients were included in the study. Analysis of controlled OS characteristics demonstrated that the duration of stimulation was significantly longer in the STOP group than in the control group (P < 0.05). Luteinizing hormone (LH) and estradiol levels on the day of human chorionic gonadotropin (hCG) administration, as well as LH levels on the day of gonadotropin (Gn) initiation, were significantly higher in the STOP group than in the control group (P < 0.05). No significant differences were observed between the groups in the total Gn dose administered or the number of follicles ≥ 16 mm on the day of hCG administration (P > 0.05). Retrieved oocytes and metaphase II (MII) oocytes were significantly higher in the STOP group (P < 0.05). However, no significant differences were found between the two groups in clinical outcomes, including implantation rate, clinical pregnancy rate, and miscarriage rate (P > 0.05).
conclusionThe STOP protocol effectively increases the numbers of retrieved oocytes and MII oocytes in patients with POR. However, it does not significantly improve embryo development outcomes or clinical pregnancy outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.